QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
NASDAQ:NEO

NeoGenomics (NEO) Stock Forecast, Price & News

$17.36
-0.08 (-0.46%)
(As of 06/8/2023 ET)
Compare
Today's Range
$17.00
$17.79
50-Day Range
$14.10
$19.83
52-Week Range
$6.00
$20.54
Volume
741,173 shs
Average Volume
1.09 million shs
Market Capitalization
$2.21 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.55

NeoGenomics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.73 Rating Score
Upside/​Downside
12.6% Upside
$19.55 Price Target
Short Interest
Bearish
6.20% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.55mentions of NeoGenomics in the last 14 days
Based on 11 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.52) to ($0.38) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.44 out of 5 stars

Medical Sector

918th out of 986 stocks

Testing Laboratories Industry

1st out of 1 stocks


NEO stock logo

About NeoGenomics (NASDAQ:NEO) Stock

NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. It operates through the Clinical Services and Pharma Services segments. The Clinical Services segment offers cancer testing services to community-based pathologists, hospitals, academic centers, and oncology groups. The Pharma Services segment focuses on supporting pharmaceutical firms in drug development programs by supporting various clinical trials and research. It also provides testing services in support of its pharmaceutical clients' oncology programs from discovery to commercialization. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.

Receive NEO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeoGenomics and its competitors with MarketBeat's FREE daily newsletter.

NEO Stock News Headlines

NeoGenomics (NASDAQ:NEO) Releases FY 2023 Earnings Guidance
"Unknown laser company making HUGE profit from Russia-Ukraine War"
On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>
SVB Securities Reaffirms Their Buy Rating on NeoGenomics (NEO)
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
NeoGenomics: What Lies Ahead
NeoGenomics (NASDAQ:NEO) Shares Gap Down to $19.13
5 Huge Analyst Calls
NeoGenomics: Q1 Earnings Insights
Analyst Expectations for NeoGenomics's Future
NeoGenomics: Q1 Earnings Snapshot
BTIG Upgrades Neogenomics (NEO)
NeoGenomics Reports First Quarter 2023 Results
See More Headlines

NEO Price History

NEO Company Calendar

Last Earnings
11/04/2021
Today
6/08/2023
Next Earnings (Estimated)
8/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Testing laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NEO
Employees
2,100
Year Founded
2002

Price Target and Rating

Average Stock Price Forecast
$19.55
High Stock Price Forecast
$25.00
Low Stock Price Forecast
$15.00
Forecasted Upside/Downside
+12.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.73
Research Coverage
11 Analysts

Profitability

Net Income
$-144,250,000.00
Pretax Margin
-26.41%

Debt

Sales & Book Value

Annual Sales
$509.73 million
Book Value
$7.90 per share

Miscellaneous

Free Float
125,919,000
Market Cap
$2.21 billion
Optionable
Optionable
Beta
1.10

Social Links


Key Executives

  • Chris Smith
    Chief Executive Officer & Director
  • Jeffrey Scott Sherman
    Chief Financial Officer
  • Steven A. Ross
    Chief Information Officer & Vice President
  • David Sholehvar
    President-Clinical Services
  • John Mooney
    Chief Technology Officer













NEO Stock - Frequently Asked Questions

Should I buy or sell NeoGenomics stock right now?

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NeoGenomics in the last year. There are currently 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" NEO shares.
View NEO analyst ratings
or view top-rated stocks.

What is NeoGenomics' stock price forecast for 2023?

11 analysts have issued 12-month target prices for NeoGenomics' shares. Their NEO share price forecasts range from $15.00 to $25.00. On average, they expect the company's stock price to reach $19.55 in the next year. This suggests a possible upside of 12.6% from the stock's current price.
View analysts price targets for NEO
or view top-rated stocks among Wall Street analysts.

How have NEO shares performed in 2023?

NeoGenomics' stock was trading at $9.24 on January 1st, 2023. Since then, NEO stock has increased by 87.9% and is now trading at $17.36.
View the best growth stocks for 2023 here
.

When is NeoGenomics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our NEO earnings forecast
.

How were NeoGenomics' earnings last quarter?

NeoGenomics, Inc. (NASDAQ:NEO) issued its quarterly earnings data on Thursday, November, 4th. The medical research company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.01. The medical research company earned $121.30 million during the quarter, compared to the consensus estimate of $125.09 million. NeoGenomics had a negative net margin of 23.72% and a negative trailing twelve-month return on equity of 7.34%. NeoGenomics's quarterly revenue was down 3.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.04 EPS.

What guidance has NeoGenomics issued on next quarter's earnings?

NeoGenomics updated its FY 2023 earnings guidance on Wednesday, June, 7th. The company provided EPS guidance of -$0.36--$0.30 for the period, compared to the consensus estimate of -$0.42. The company issued revenue guidance of $555.00 million-$565.00 million, compared to the consensus revenue estimate of $549.82 million.

What is Douglas M. VanOort's approval rating as NeoGenomics' CEO?

116 employees have rated NeoGenomics Chief Executive Officer Douglas M. VanOort on Glassdoor.com. Douglas M. VanOort has an approval rating of 98% among the company's employees. This puts Douglas M. VanOort in the top 20% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of NeoGenomics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NeoGenomics investors own include Marvell Technology (MRVL), NVIDIA (NVDA), Alibaba Group (BABA), Block (SQ), Inseego (INSG), PayPal (PYPL), Micron Technology (MU), Invitae (NVTA), CRISPR Therapeutics (CRSP) and AbbVie (ABBV).

What is NeoGenomics' stock symbol?

NeoGenomics trades on the NASDAQ under the ticker symbol "NEO."

Who are NeoGenomics' major shareholders?

NeoGenomics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Brown Advisory Inc. (5.17%), State Street Corp (3.83%), Greenhouse Funds LLLP (2.30%), First Light Asset Management LLC (2.12%), Dimensional Fund Advisors LP (2.11%) and Geode Capital Management LLC (1.97%). Insiders that own company stock include Bruce K Crowther, Douglas Matthew Brown, George Cardoza, Jennifer Balliet, Kathryn B Mckenzie, Kevin C Johnson, Lawrence Martin Weiss, Mark Mallon, Oort Douglas M Van, Robert J Shovlin, Steven C Jones and William Bonello.
View institutional ownership trends
.

How do I buy shares of NeoGenomics?

Shares of NEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NeoGenomics' stock price today?

One share of NEO stock can currently be purchased for approximately $17.36.

How much money does NeoGenomics make?

NeoGenomics (NASDAQ:NEO) has a market capitalization of $2.21 billion and generates $509.73 million in revenue each year. The medical research company earns $-144,250,000.00 in net income (profit) each year or ($1.01) on an earnings per share basis.

How many employees does NeoGenomics have?

The company employs 2,100 workers across the globe.

Does NeoGenomics have any subsidiaries?
The following companies are subsidiares of NeoGenomics: Clarient Inc., Clarient Diagnostic Services Inc, Clarient Inc, Cynogen Inc., GE Medical Holding AB., Genesis Acquisition Holding Corp, Genesis Acquisition Holdings Corp., Genoptix, Genoptix Inc., Inivata Inc., Inivata Limited, Inivata Limited., Minuet Diagnostics Inc., NeoGenomics Bioinformatics Inc., NeoGenomics Europe SA, NeoGenomics Foundation Inc, NeoGenomics Laboratories Inc, NeoGenomics Singapore Pte. Ltd, Path Labs LLC, Suzhou NeoGenomics Pharmaceutical Research Co. Limited, Trapelo Health, and Trapelo Health LLC.
Read More
How can I contact NeoGenomics?

NeoGenomics' mailing address is 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913. The official website for the company is www.neogenomics.com. The medical research company can be reached via phone at (239) 768-0600, via email at sjones@neogenomics.com, or via fax at 239-690-4237.

This page (NASDAQ:NEO) was last updated on 6/8/2023 by MarketBeat.com Staff

My Account -